DIAGNOS Inc. (DGNOF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DIAGNOS Inc. (DGNOF) trades at $0.18 with AI Score 36/100 (Grade D). DIAGNOS Inc. specializes in software-based healthcare services, primarily Computer Assisted Retina Analysis (CARA), a tool for detecting diabetic retinopathy. Market cap: $18.03M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for DGNOF: DGNOF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DGNOF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DGNOF: 1/1 perspectives are bearish.
How is this calculated? →DIAGNOS Inc. (DGNOF) Healthcare & Pipeline Overview
DIAGNOS Inc. provides software-based healthcare solutions, focusing on early detection of diabetic retinopathy through its CARA platform. Operating across several countries, the company leverages AI and data analysis to enhance diagnostic capabilities for eye care professionals, positioning itself in the evolving landscape of healthcare information services.
What Is the Investment Thesis for DGNOF?
DIAGNOS Inc. presents a speculative investment opportunity within the healthcare information services sector. The company's CARA platform addresses a critical need for early detection of diabetic retinopathy, a growing concern globally. However, with a negative P/E ratio of -7.48 and a significantly negative profit margin of -6907.3%, the company's financial performance raises concerns about its profitability and sustainability. The potential for growth lies in expanding the adoption of the CARA platform and leveraging its AI and data analysis capabilities. Investors should closely monitor the company's ability to improve its financial metrics and secure additional contracts in its target markets. The low Beta of -0.17 suggests the stock is less volatile than the market, but this may also reflect limited trading activity and investor interest.
Based on FMP financials and quantitative analysis
DGNOF Key Highlights
- Market capitalization of $18.03M indicates a micro-cap company with potential for high growth but also significant risk.
- Negative P/E ratio of -7.48 reflects current unprofitability, requiring careful monitoring of future earnings potential.
- Gross margin of -2090.9% signals substantial challenges in cost management and pricing strategies.
- The company's focus on Computer Assisted Retina Analysis (CARA) positions it in a niche market with potential for expansion.
- Operations across multiple countries, including Canada, the United States, and several Latin American nations, provide geographic diversification.
Who Are DGNOF's Competitors?
DGNOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BBIXF Bonus BioGroup Ltd. | $0.11 | +0.00% | $128.47M | 48 |
| BMKDF BioMark Diagnostics Inc. | $0.41 | +0.00% | $43.12M | 47 |
| CLIFF Cordlife Group Limited | $0.15 | +0.00% | $38.57M | 53 |
| CLYYF Celyad Oncology S.A. | $0.25 | +0.00% | $11.19M | 61 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DGNOF's Key Strengths?
- Proprietary CARA platform for diabetic retinopathy detection.
- Expertise in AI and data analysis.
- Established presence in multiple countries.
- Focus on a specific niche within healthcare.
What Are DGNOF's Weaknesses?
- Negative P/E ratio and profit margin.
- Limited financial resources.
- Reliance on a single product (CARA).
- Small market capitalization.
What Could Drive DGNOF Stock Higher?
- Potential new partnerships with healthcare providers to expand CARA platform adoption.
- Increasing prevalence of diabetes driving demand for diabetic retinopathy detection solutions.
- Development of new AI-powered diagnostic tools to diversify revenue streams.
What Are the Key Risks for DGNOF?
- Financial-distress signal — its Altman Z-Score of -31.06 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger healthcare companies with more resources.
- Regulatory changes in healthcare affecting the adoption of AI-powered diagnostic tools.
- Negative P/E ratio and profit margin indicating financial instability.
- Limited liquidity and wider bid-ask spreads on the OTC market.
What Are the Growth Opportunities for DGNOF?
- Expansion of CARA Platform Adoption: DIAGNOS has the opportunity to increase the adoption of its CARA platform among healthcare providers globally. The rising prevalence of diabetes and the need for early detection of diabetic retinopathy create a significant market. By targeting regions with limited access to specialized eye care, DIAGNOS can expand its market share and generate recurring revenue through software subscriptions and service fees. Market research indicates the global diabetic retinopathy market is projected to reach $4.6 billion by 2027, offering substantial growth potential.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with hospitals, clinics, and eye care centers can accelerate the adoption of DIAGNOS's CARA platform. These partnerships can provide access to a broader patient base and facilitate the integration of CARA into existing clinical workflows. By collaborating with key opinion leaders and participating in industry conferences, DIAGNOS can enhance its visibility and credibility within the healthcare community. The timeline for establishing these partnerships is estimated at 1-2 years, with potential revenue impact within 2-3 years.
- Development of New AI-Powered Diagnostic Tools: DIAGNOS can leverage its expertise in AI and data analysis to develop new diagnostic tools for other medical conditions. By expanding its product portfolio, the company can diversify its revenue streams and reduce its reliance on a single product. Potential areas for expansion include cardiovascular disease, neurological disorders, and cancer screening. The development of new AI-powered diagnostic tools requires significant investment in research and development, with a timeline of 2-3 years for product launch.
- Geographic Expansion into Emerging Markets: DIAGNOS can expand its geographic presence into emerging markets with high rates of diabetes and limited access to specialized eye care. These markets offer significant growth potential due to the unmet need for affordable and accessible diagnostic solutions. By adapting its CARA platform to local languages and regulatory requirements, DIAGNOS can penetrate these markets and establish a strong foothold. The timeline for geographic expansion is estimated at 1-2 years, with potential revenue impact within 2-3 years.
- Leveraging Telemedicine for Remote Diagnostics: Integrating the CARA platform with telemedicine services can enable remote diagnostics and expand access to eye care in underserved areas. By partnering with telemedicine providers, DIAGNOS can offer its diagnostic services to patients who may not have access to traditional healthcare facilities. This approach can also reduce the cost of healthcare delivery and improve patient outcomes. The integration of CARA with telemedicine platforms requires collaboration with technology providers and regulatory approvals, with a timeline of 1-2 years for implementation.
What Opportunities Does DGNOF Have?
- Expansion of CARA platform adoption.
- Strategic partnerships with healthcare providers.
- Development of new AI-powered diagnostic tools.
- Geographic expansion into emerging markets.
What Threats Does DGNOF Face?
- Competition from larger healthcare companies.
- Regulatory changes in healthcare.
- Technological advancements that could render CARA obsolete.
- Economic downturn affecting healthcare spending.
What Are DGNOF's Competitive Advantages?
- Proprietary Computer Assisted Retina Analysis (CARA) software.
- Expertise in AI and data analysis for healthcare.
- Established presence in multiple countries.
- Partnerships with healthcare providers.
What Does DGNOF Do?
Founded in 1998 and headquartered in Brossard, Canada, DIAGNOS Inc. has established itself as a provider of software-based services within the healthcare sector. The company's core offering is the Computer Assisted Retina Analysis (CARA) platform, a web-based tool designed to aid healthcare professionals in the early detection of diabetic retinopathy. This technology allows eye care specialists to visualize retinal landmarks and identify pathological changes indicative of the disease. DIAGNOS operates across Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica, reflecting a global reach in its service delivery. Beyond its diagnostic software, DIAGNOS also provides consulting services in data analysis and artificial intelligence, leveraging its expertise to offer broader solutions within the healthcare industry. The company's focus on innovative technology and international expansion underscores its commitment to improving healthcare outcomes through advanced diagnostic tools and services.
What Products and Services Does DGNOF Offer?
- Provides Computer Assisted Retina Analysis (CARA) software.
- CARA assists in the early detection of diabetic retinopathy.
- Offers a web-based platform for healthcare professionals.
- Visualizes retinal landmarks and pathological changes.
- Provides consulting services in data analysis.
- Offers expertise in artificial intelligence for healthcare applications.
How Does DGNOF Make Money?
- Software-as-a-Service (SaaS) model for the CARA platform.
- Revenue from subscriptions and service fees.
- Consulting services in data analysis and AI.
- Partnerships with healthcare providers and telemedicine companies.
What Industry Does DGNOF Operate In?
DIAGNOS Inc. operates within the healthcare information services sector, which is experiencing growth driven by technological advancements and increasing demand for efficient diagnostic tools. The market for AI-powered diagnostic solutions is expanding, with companies like DIAGNOS leveraging these technologies to improve healthcare outcomes. The competitive landscape includes established players in medical imaging and diagnostics, as well as emerging companies focused on AI-driven healthcare solutions. DIAGNOS's focus on diabetic retinopathy detection positions it within a specific niche of the broader healthcare IT market.
Who Are DGNOF's Key Customers?
- Eye care specialists
- Hospitals and clinics
- Healthcare providers
- Telemedicine companies
How DIAGNOS Inc. Is Valued
DIAGNOS Inc. carries a market capitalization of $18.03M, placing it in the micro-cap category. Relative to its peer group, DGNOF's quantitative score of 36/100 is below the peer average of 56/100.
Key Financial Metrics
Its free cash flow yield is -15.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.49 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
DIAGNOS Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -31.06 places it in the distress zone, a signal of elevated financial risk.
DGNOF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Proprietary CARA platform for diabetic retinopathy detection.
- Expertise in AI and data analysis.
- Established presence in multiple countries.
- Focus on a specific niche within healthcare.
Bear Case
- Negative P/E ratio and profit margin.
- Limited financial resources.
- Reliance on a single product (CARA).
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
DGNOF Latest News
No recent news available for DGNOF.
DGNOF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DGNOF.
Price Targets
Wall Street price target analysis for DGNOF.
DGNOF MoonshotScore
What does this score mean?
The MoonshotScore rates DGNOF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Andre Larente
CEO
Andre Larente serves as the CEO of DIAGNOS Inc. His background includes experience in the technology and healthcare sectors. He has been involved in the development and commercialization of innovative healthcare solutions. Larente's expertise lies in strategic planning, business development, and market expansion. He is responsible for driving the company's growth and executing its strategic vision. His leadership aims to position DIAGNOS as a leading provider of AI-powered diagnostic solutions.
Track Record: Under Andre Larente's leadership, DIAGNOS Inc. has focused on expanding the adoption of its CARA platform and developing new AI-powered diagnostic tools. He has overseen the company's efforts to secure partnerships with healthcare providers and expand its geographic presence. Key milestones include the commercialization of the CARA platform in multiple countries and the development of new AI algorithms for disease detection. His tenure has been marked by a focus on innovation and strategic growth.
DGNOF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that DIAGNOS Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial disclosures. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ, as they may lack the same level of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and wider bid-ask spreads.
- Lack of regulatory oversight and transparency.
- Potential for price manipulation and fraud.
- Higher risk of financial distress or bankruptcy.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Established presence in multiple countries.
- Proprietary CARA platform for diabetic retinopathy detection.
- Partnerships with healthcare providers.
- Focus on AI and data analysis for healthcare applications.
DGNOF Healthcare Stock FAQ
What does DIAGNOS Inc. do?
DIAGNOS Inc. specializes in providing software-based healthcare services, primarily focusing on the early detection of diabetic retinopathy through its Computer Assisted Retina Analysis (CARA) platform. This web-based tool assists healthcare professionals in visualizing retinal landmarks and identifying pathological changes indicative of the disease. In addition to its diagnostic software, DIAGNOS offers consulting services in data analysis and artificial intelligence, catering to the broader needs of the healthcare industry. The company operates across multiple countries, including Canada, the United States, and several Latin American nations, reflecting its global reach and commitment to improving healthcare outcomes through advanced technology.
What do analysts say about DGNOF stock?
As of March 16, 2026, there is limited analyst coverage specifically for DGNOF stock due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio and profit margin, suggest that the company is currently unprofitable. Growth considerations revolve around the successful adoption of the CARA platform and the development of new AI-powered diagnostic tools. Investors should conduct their own thorough research and consider the risks associated with investing in micro-cap companies on the OTC market. There is no consensus rating available.
What are the main risks for DGNOF?
The main risks for DIAGNOS Inc. include its negative financial performance, as indicated by its negative P/E ratio and profit margin, which raises concerns about its financial sustainability. Competition from larger healthcare companies with more resources poses a threat to its market share. Regulatory changes in healthcare could affect the adoption of its AI-powered diagnostic tools. Additionally, the company's reliance on a single product (CARA) makes it vulnerable to technological advancements that could render its platform obsolete. As an OTC-listed stock, DGNOF also faces risks related to limited liquidity and transparency.
What are the key factors to evaluate for DGNOF?
DIAGNOS Inc. (DGNOF) holds an AI score of 36/100 (low). Not financial advice.
How frequently does DGNOF data refresh on this page?
DGNOF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DGNOF's recent stock price performance?
DIAGNOS Inc. (DGNOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary CARA platform for diabetic retinopathy detection. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DGNOF overvalued or undervalued right now?
Valuing DIAGNOS Inc. (DGNOF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DGNOF?
Before investing in DIAGNOS Inc. (DGNOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for DGNOF.
- Financial data based on available information as of 2026-03-16.
- OTC market investments carry higher risk.